1318 related articles for article (PubMed ID: 29545067)
21. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
Kappos L; Bar-Or A; Cree BAC; Fox RJ; Giovannoni G; Gold R; Vermersch P; Arnold DL; Arnould S; Scherz T; Wolf C; Wallström E; Dahlke F;
Lancet; 2018 Mar; 391(10127):1263-1273. PubMed ID: 29576505
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial.
Kappos L; Arnold DL; Bar-Or A; Camm J; Derfuss T; Kieseier BC; Sprenger T; Greenough K; Ni P; Harada T
Lancet Neurol; 2016 Oct; 15(11):1148-59. PubMed ID: 27543447
[TBL] [Abstract][Full Text] [Related]
23. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.
Zajicek J; Ball S; Wright D; Vickery J; Nunn A; Miller D; Cano MG; McManus D; Mallik S; Hobart J;
Lancet Neurol; 2013 Sep; 12(9):857-865. PubMed ID: 23856559
[TBL] [Abstract][Full Text] [Related]
24. Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study.
Saida T; Kira JI; Kishida S; Yamamura T; Sudo Y; Ogiwara K; Tibung JT; Lucas N; Subramanyam M;
Mult Scler Relat Disord; 2017 Jan; 11():25-31. PubMed ID: 28104251
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
[TBL] [Abstract][Full Text] [Related]
26. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
27. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
[TBL] [Abstract][Full Text] [Related]
28. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X; Hauser SL; Kappos L; Arnold DL; Bar-Or A; Comi G; de Seze J; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Rammohan KW; Selmaj K; Traboulsee A; Sauter A; Masterman D; Fontoura P; Belachew S; Garren H; Mairon N; Chin P; Wolinsky JS;
N Engl J Med; 2017 Jan; 376(3):209-220. PubMed ID: 28002688
[TBL] [Abstract][Full Text] [Related]
29. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
Kappos L; Wolinsky JS; Giovannoni G; Arnold DL; Wang Q; Bernasconi C; Model F; Koendgen H; Manfrini M; Belachew S; Hauser SL
JAMA Neurol; 2020 Sep; 77(9):1132-1140. PubMed ID: 32511687
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
[TBL] [Abstract][Full Text] [Related]
31. Predictors of Health Utility in Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies.
Hernandez L; O'Donnell M; Postma M;
Pharmacoeconomics; 2021 Feb; 39(2):243-256. PubMed ID: 32989685
[TBL] [Abstract][Full Text] [Related]
32. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
Holmén C; Piehl F; Hillert J; Fogdell-Hahn A; Lundkvist M; Karlberg E; Nilsson P; Dahle C; Feltelius N; Svenningsson A; Lycke J; Olsson T
Mult Scler; 2011 Jun; 17(6):708-19. PubMed ID: 21228027
[TBL] [Abstract][Full Text] [Related]
33. Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial.
Fox EJ; Markowitz C; Applebee A; Montalban X; Wolinsky JS; Belachew S; Fiore D; Pei J; Musch B; Giovannoni G
Mult Scler; 2018 Dec; 24(14):1862-1870. PubMed ID: 30415593
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
Comi G; Kappos L; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Ding N; Cohen JA;
Lancet Neurol; 2019 Nov; 18(11):1009-1020. PubMed ID: 31492651
[TBL] [Abstract][Full Text] [Related]
35. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Calabresi PA; Kieseier BC; Arnold DL; Balcer LJ; Boyko A; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A;
Lancet Neurol; 2014 Jul; 13(7):657-65. PubMed ID: 24794721
[TBL] [Abstract][Full Text] [Related]
36. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.
Panitch H; Miller A; Paty D; Weinshenker B;
Neurology; 2004 Nov; 63(10):1788-95. PubMed ID: 15557491
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
Reich DS; Arnold DL; Vermersch P; Bar-Or A; Fox RJ; Matta A; Turner T; Wallström E; Zhang X; Mareš M; Khabirov FA; Traboulsee A;
Lancet Neurol; 2021 Sep; 20(9):729-738. PubMed ID: 34418400
[TBL] [Abstract][Full Text] [Related]
38. Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial.
Saida T; Kira JI; Kishida S; Yamamura T; Ohtsuka N; Ling Y; Torii S; Lucas N; Kuesters G; Steiner D; Tibung JT;
Neurol Ther; 2017 Jun; 6(1):39-55. PubMed ID: 27921221
[TBL] [Abstract][Full Text] [Related]
39. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
[TBL] [Abstract][Full Text] [Related]
40. Natalizumab for relapsing remitting multiple sclerosis.
Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
